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Abstract: Telomere biology, a key component of the hallmarks of ageing, offers insight into dysregulation
of normative ageing processes that accompany age-related diseases such as cancer. Telomere homeostasis
is tightly linked to cellular metabolism, and in particular with mitochondrial physiology, which is also
diminished during cellular senescence and normative physiological ageing. Inherent in the biochemistry
of these processes is the role of magnesium, one of the main cellular ions and an essential cofactor in
all reactions that use ATP. Magnesium plays an important role in many of the processes involved in
regulating telomere structure, integrity and function. This review explores the mechanisms that maintain
telomere structure and function, their influence on circadian rhythms and their impact on health and
age-related disease. The pervasive role of magnesium in telomere homeostasis is also highlighted.
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1. Introduction
Ageing is not a simple passive degenerative process, but one regulated by distinct biochemical
pathways. It has been classified by a number of common hallmarks that are shared across taxa. These
can be sub-classified into primary, antagonistic, and integrative hallmarks, one of which is telomere
attrition [1].
Telomeres are nucleo-protein complexes at the linear ends of vertebrate chromosomes containing
(TTAGGG)n DNA repeats, which are essential for maintaining genomic integrity [2]. Telomere attrition
is an integral part of the end replication problem [3,4] and acceleration of the rate of telomeric sequence
loss is a feature of a plethora of non-communicable diseases [5]. Telomere shortening has been reported
to accelerate in association with physical and psychological stress exposures [5]. Critical cellular
telomeric shortening can trigger a persistent DNA damage response (DDR), that signals the cell to
enter senescence, or undergo apoptosis, dependent upon the relative level of genomic damage the cell
has accrued during its replicative lifespan [2].
Telomere shortening, however, is not a unidirectional process: stem cells, cancer cells, as well
as some differentiated cells—including B and T lymphocytes—can counter telomere shortening and
maintain the length of their telomeric DNA despite mitotic activity, typically through the action of
the holoenzyme telomerase [6]. Approximately 90% of human cancers demonstrate up-regulation of
telomerase activity [7], while most of the remaining 10% use an alternative lengthening of telomeres
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(ALT) mechanism [8]. This ability to preserve telomere function is necessary to confer replicative
immortality, one of the hallmarks of cancer [9].
Telomere maintenance is a dynamic process, which is responsive to metabolic and endocrine
mediators of cellular stress [10]. Factors that mitigate the effect of cellular stress, such as free
radical scavengers and antioxidants, may thereby offer the possibility of slowing the rate of telomere
attrition [11].
2. Magnesium Homeostasis and Disease
Magnesium (Mg2+) is one of the most abundant metal ions in cells and plays a variety of
roles, including the stabilization of DNA, RNA, adenosine triphosphate (ATP), and other nucleotide
triphosphates/dioxynucleotide triphosphates (NTPs/dNTPs) [12]. It participates in over 600 enzymatic
reactions, including all those that involve ATP, and is essential for maintenance of DNA structure,
cellular excitability and cellular health span [13–15]. Mg2+ deficiency has been implicated in many
disease processes, including type 2 diabetes (T2DM) [16], Alzheimer’s disease [17], and cancer [18–21],
while Mg2+ supplementation has been shown to be beneficial for blood pressure control, endothelial
function, insulin sensitivity and T2DM [22–24]. In vitro, low [Mg2+] has also been shown to promote
traits associated with senescence in endothelial cells, including slower cell growth and up-regulation of
p21 (a cell cycle inhibitor) and IL-1α (a pro-inflammatory cytokine) [25]. However, cells appear to have
a remarkable ability to preserve intracellular [Mg2+] in spite of a low extracellular concentration of this
ion [26], or a dynamic metabolism [27]. On the other hand, intracellular [Mg2+] increases several fold
during the log phase of cell growth, in spite of a constant ATP/ADP and extracellular [Mg2+], providing
further evidence for the hypothesis that cellular [Mg2+] is actively regulated [27].
In the extracellular environment, Mg2+ is involved in inhibiting ectopic calcification, which is
a key feature of accelerated physiological ageing [28–30]. Mg2+ has been shown to interfere with the
growth of ectopic calcium phosphate crystals in blood vessels [30] and to delay the morphological shift
from primary to secondary calciprotein particle formation [31]. In addition, Mg2+ may also contribute
to the osteogenic transformation of vascular smooth muscle cells [30]. Mg2+ has been found to correlate
negatively to both Fetuin-A and FGF23 in serum [32]. Fetuin-A is a major calcification inhibitor in
the circulation [31,32], while FGF23 is an endocrine factor that can contrast calcification by inducing
phosphate excretion [33,34].
Mg2+ transport across membranes is still poorly understood, but homeostasis at an organismal
level appears to be maintained by modulating absorption in the intestine and reabsorption in the
kidney [30,35]. In both cases, Mg2+ is imported apically by TRPM6 channels, transferred paracellularly
across tight junctions with the contribution of claudin-16 and claudin-19, and exported basolaterally
by the SLC41A1 Na/Mg exchanger [35,36]. In all cell types, Mg2+ is imported by TRPM7 channels
and exported by the action of SLC41A1 [35,36]. Another important member of the SLC41 family is the
Na/Mg exchanger SLC41A3, which is involved in transport across the mitochondrial membrane along
with the Mrs2 channel [35–37].
3. Magnesium and Telomeres
Cytosolic Mg2+ concentration is approximately 1 mM [30], but significant reserves are present
in bound form, mainly chelated by ATP, or within intracellular compartments, especially inside
the mitochondria [38]. In a manner analogous to the regulation of calcium biochemistry, release
or uptake of Mg2+ can cause large local shifts in [Mg2+], which in turn can regulate a variety of
processes, including the regulation of flow of metabolites through glycolysis, the TCA cycle, oxidative
phosphorylation, and ATP export from the mitochondria [38]. Critically, Mg2+ plays a role in telomere
maintenance and the activity of telomerase [39]. These interactions are discussed in context in the
following sections.
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3.1. Telomere Attrition
The main driver of telomere attrition is DNA replication. However, the amount of telomeric
sequence loss can vary dramatically, from the theoretical minimum of less than 10 base pairs (bp)
lost per replication, to an average of 50–200 bp, up to about one thousand bp [40]. Reactive oxygen
species (ROS) and oxidative stress produced by dysfunctional mitochondria can accelerate telomere
attrition [40,41], while reducing ROS can mitigate this effect [11].
Telomeric sequences display a particular sensitivity to ROS-induced damage, as they are
guanine-rich (G-rich) and have stacked G repeats. G has the lowest oxidation potential among
the four DNA bases [42,43], and vulnerability to oxidative stress increases exponentially when G
nucleotides are stacked [44]. The human telomeric DNA repeat stretch has been shown to be more
sensitive to strand breakage, particularly at the G repeat, compared to non-telomeric sequences [45–48].
Additionally, DNA repair appears to be less efficient at telomeres in comparison to the rest of the
genome [41]. The shelterin protein complex, which ‘caps’ telomeres, provides protection and impairs
access to nucleases [49]. This prevents telomere ends from being recognised as DNA breaks, from
being subjected to nuclease activity inherent in DNA repair processes, and from acting as a trigger
for apoptosis [50]. In light of these considerations, it is thought that higher levels of ROS lead to
an accumulation of unrepaired DNA damage at the telomeric region, which causes a larger DNA
sequence loss during subsequent replication [40,51]. As such, the stacked G nucleotides integral to
telomere structure may act as a redox-sensitive ‘alarm system’ that senses and signals the presence of
oxidative damage before it can cause significant damage to the rest of the genome.
Secondary telomeric DNA structure is also important for telomere maintenance. In particular, it
has been shown that the formation of G-quadruplexes prevents DNA repair machinery and telomerase
from accessing the telomeric region [49,52]. G-quadruplexes can be formed by either a single DNA
strand, or multiple DNA strands, when four G bases join by Hoogsteen hydrogen bonding to form
a square planar structure called a G-tetrad, and two or more G-tetrads stack on top of each other in the
presence of monovalent K+ and Na+ ions to form a G-quadruplex (Figure 1) [53]. G-quadruplexes may
form stable nano-wires (G-wires) when guanine-rich DNA strands are annealed in the presence of
suitable divalent cations [54]. Mg2+ can cause a configuration switch in G-quadruplex structures [55]
and has been reported to stabilise G-wires [53,56]. G-wires are highly resistant to denaturation and
have been reported to interfere with telomerase function [53,55,57]. In addition, some proteins appear
to recognise specifically G-quadruplex structures, such as the GAR domain of the shelterin protein
TRF2 [58].
Mg2+ has been reported to enhance the stability of G-quadruplexes at oncogene promoter
regions and prevent conversion to their pro-oncogene duplex form [59] and thus can act as an off
switch in transcriptional regulation [60]. For instance, the promoter of the proto-oncogene c-Myc
contains a parallel-stranded G-quadruplex that appears to bind Mg2+ most avidly [53,59]. Telomere
attrition was found to be faster when cells were cultured in Mg2+-deficient conditions [26]. It has
recently been reported that telomere G-quadruplexes may render DNA particularly sensitive to direct
ultra-violet radiation (UV) damage and allow the oxidation of telomeric Gs even at wavelengths
that are below the G ionization potential [61]. The implications of this observation for cancer
neogenesis, progression and treatment remain to be explored. Recently, however, melanoma risk
among individuals with light skin has been hypothesised to be mitigated by shortening of their
telomeres through polygenic adaptation [62]. This may explain, in part, the shorter telomere lengths in
Caucasians than in sub-Saharan Africans [63]. G quadruplex sensitivity to UV light may thus provide
a mechanistic/structural basis for telomeres within the framework of such polygenic adaptation and
cancer risk.
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Figure 1. Schematic representation of an antiparallel G-quadruplex formed from a single DNA strand. 
This type of structure can form at telomere ends, protecting and stabilising the single strand overhang. 
The G-quadruplex is composed of several stacked G-tetrads, each of which is in turn formed by four 
guanines (G) joined by Hoogsteen hydrogen bonding and stabilised by a monovalent cation (K+ in 
this figure). 
3.2. Magnesium and Telomeric Structure 
Telomeric chromatin structure and integrity is impacted upon by Mg2+ biochemistry [39]. In 
particular, this can involve regulation and maintenance of higher order telomeric chromatin 
structure. More than 50% of telomeres localise to the lamina, a scaffold of intermediate filaments 
called lamins, that contributes to chromatin organisation, supports the mechanical stability of the 
nucleus, while also modulating signal transduction and transcription regulation [64,65]. The nuclear 
lamina comprises two lamin types, A and B, which are organised into distinct but overlapping 
networks that perform different functions within the nucleus [64]. Modulation of the lamin tail 
domain, which is recognised by lamin-binding proteins and provides an attachment site for 
chromatin and other structural proteins, has been demonstrated to be dependent on the presence of 
Mg2+ [64]. Lamin B1 has been shown to be sensitive to Mg2+ [64]. Down-regulation of lamin B1 is 
required for progression to full senescence, which triggers both local and global chromatin 
modifications [65]. Indeed, the decrease of lamin B1 can serve as a biomarker of senescence [66]. 
3.3. The Role of Telomeric Repeat-Containing RNA (TERRA) 
Regulation of higher order telomeric structure is also a general feature of the epigenetic 
landscape and involves non-canonical epigenetic modifiers, such as non-coding RNAs (ncRNAs).  
An important player in this context is TERRA, a class of long ncRNA (lncRNA) transcribed from 
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which triggers both local and global chromatin modifications [65]. Indeed, the ecrease of la in B1
can serve as a biomarker of s nes ence [66].
3.3. The Role of Telomeric Repeat-Containing RNA (TERRA)
Regulation of higher order telomeric structure is also a general feature of the epigenetic landscape
and involves non-canonical epigenetic modifiers, such as non-coding RNAs (ncRNAs). An important
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player in this context is TERRA, a class of long ncRNA (lncRNA) transcribed from insulated promoters
within telomeric and sub-telomeric regions that largely escape heterochromatinization. This class of
RNA varies considerably in length, from approximately 100 bases to 9 kilobases (kb), and contains
telomeric repeats [58]. The accumulation of mutations within the sequence allows TERRA to have,
at the same time, specific binding in cis to the telomere of origin and generalised activity in trans on
any chromosome [67].
While the picture of TERRA’s full role inside the cell is not yet clear, evidence has been accumulating
on TERRA fulfilling a variety of functions related to telomere maintenance [58,67,68]. TERRA can
interact with telomeric DNA to form hybrid DNA-RNA G-quadruplexes, interact with components of
the shelterin complex, and bind telomerase [58]. TERRA is also thought to play a role in organising
and expanding telomeric heterochromatin [69] and to help in telomere homeostasis. Indeed, TERRA
appears to be expressed at a higher rate from short telomeres, to nucleate enzyme clusters by binding to
multiple telomerase copies, and to recruit them to its telomere of origin [67].
3.4. Telomerase Activity in the Nucleus
Apart from its contribution to the maintenance of telomere structure and function, Mg2+ also
has implications for the regulation of telomerase activity. The telomerase holoenzyme is formed
by two essential components, the telomerase RNA that provides the template sequence for reverse
transcription (TERC) and the catalytic protein component, telomerase reverse transcriptase (TERT),
as well as by a number of accessory proteins [70]. It preferentially elongates short telomeres, because
the stability of the shelterin complex is higher on longer telomeres [71]. This canonical function of
telomerase requires Mg2+, which has therefore the potential to modulate its activity [6,39]. As with
telomere shortening, elongation is also restricted to the S phase of the cell cycle, which is the only point
at which active telomerase can access and elongate telomeres [71].
Interestingly, TERT is known to be subject to alternative splicing, with more than 20 known
isoforms described in man, many of which lack a functional reverse transcriptase (RT) domain [72,73].
These isoforms have been hypothesised to act as antagonists and compete in binding TERC, and to be
involved in some of the non-canonical functions of TERT which appear to be largely TERC-independent
and even RT-independent [74]. These are discussed below.
3.5. Non-Canonical TERT Functions in the Nucleus
In the nucleus, TERT can act as a transcription factor (TF) and affect genes involved in energy
metabolism, ‘stemness’, and proliferation, including the up-regulation of transfer RNA (tRNA)
transcription, interaction with NF-κB and β-catenin to activate their respective pathways, and regulation
of cyclin D1 expression [70]. Interestingly,β-catenin has, in turn, been shown to bind to the TERT promoter,
suggesting a possible feed-forward loop that supports stemness and proliferation in wnt-dependent
cancers [70].
Another emerging role for TERT is as an RNA-dependent RNA polymerase [73]. Human TERT
(hTERT) has been shown in cancer cells to catalyse the creation of double-stranded RNA (dsRNA)
from a non-coding RNA template, which is processed as a small interfering RNA (siRNA) and induces
silencing, targeting in particular transcription from centromeres and transposons and possibly helping
in the maintenance of heterochromatin [73].
3.6. Non-Canonical TERT Functions in the Mitochondria
TERT is known to be shuttled between the nucleus, cytoplasm, and mitochondrion [10]. The localisation
of TERT within different cellular sub-compartments is a responsive process, which is regulated by growth
factors, oxidative stress, caloric restriction [75], as well as antigen exposure in lymphocytes [76]. During
increased oxidative stress, TERT is excluded from the nucleus and translocates to the mitochondria where it
is reported to exert an antioxidant effect and promote mitochondrial health and cell survival [76]. Indeed,
dampening of mitochondrial ROS production correlates with mitochondrial TERT accumulation [75].
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The exact role of TERT in mitochondria is not yet clear, but several possibilities have been proposed. It has
been shown to increase potential across the inner mitochondrial membrane, decrease ROS production,
protect mitochondrial DNA (mtDNA) from damage, inhibit intrinsic apoptosis, and up-regulate activity
and efficiency of the electron transport chain (ETC) [73,74].
TERT may also be tied to the general energy metabolism of the cell by interacting with the
mammalian target of rapamycin (mTOR) pathway and the activities of the sirtuin family, key mediators
in the mitochondrion-telomere-ribosome biogenesis (MTR) trinity and regulators of the cellular
epigenetic landscape.
3.7. Telomeres and mTOR
The mammalian target of rapamycin complex 1 (mTORC1) pathway plays a crucial role in
integrating signals from growth factor and nutrient availability sensors, and in regulating a variety
of metabolic downstream pathways, including protein synthesis, cell cycle progression, energy
metabolism, mitochondrial function, autophagy, and cell survival [77]. Intriguingly, hTERT has
been shown to bind to and inhibit mTORC1, leading to increased autophagy [78] and possibly
mimicking other effects of caloric restriction (CR). Conversely, mTOR activation of TERT has also been
proposed [79].
Notably, mTOR demonstrates high sensitivity to Mg2+ oscillations [80] and it is therefore possible
that Mg2+ acts as a regulator of the balance between anabolism and catabolism [81]. The observation
that serum [Mg2+] increases in animals undergoing hibernation, or torpor, supports this hypothesis,
because this increase cannot be due to nutrition and is therefore likely to be the result of extrusion from
cells [81]. It is worth mentioning that depletion of cellular Mg2+ reserves, with likely repercussions on
the metabolic balance, has been identified as both a cause and a consequence of ageing [26,39,82].
4. Mitochondrial Health, Ageing and Cancer
Mitochondrial homeostasis has been shown to deteriorate with age [83,84], and multiple
mechanisms link it to telomere attrition [11]. An adequate concentration of mitochondrial Mg2+
([Mg2+]mito) is essential for maintaining the integrity of the electron transport chain, as well as
for controlling the flow of metabolites through glycolysis and the TCA cycle [38]. Consequently,
[Mg2+]mito is a key determinant of cellular oxidative resilience, i.e., the ability to prevent or
repair oxidative damage. This is pertinent, as mitochondrial dysfunction leads to increased ROS
production, which in turn causes increased DNA damage and accelerated telomere attrition [11].
Furthermore, mitochondrial dysfunction induces specific nuclear gene expression through “retrograde
signalling” [76].
On the other hand, telomere dysfunction activates p53 signalling, which represses the expression
of PGC1-α/β, the master regulators of mitochondrial biogenesis [85]. In addition, a PGC1-α/β-
independent pathway has been described, and its activity has been shown to decline during ageing
along with changes in mitochondrial nicotinamide adenine dinucleotide (NAD+ levels [86]. This
decline can be reversed if intramitochondrial NAD+ is increased by supplementation of its metabolic
precursor nicotinamide mononucleotide (NMN) [86]. The decline in mitochondrial NAD+ appears to
be due to an imbalance between nuclear and mitochondrial-encoded subunits, which is associated
with an accumulation of HIF-1α, creating a pseudohypoxic state in spite of normal oxygen levels [86].
In mice, deletion of SIRT1 accelerates HIF-1α production, whereas raising NAD+ levels in old mice
restores mitochondrial function to that of a young mouse in a SIRT1-dependent manner [86].
Interestingly, Mg2+ deficiency was shown to decrease resistance to hypoxia in vivo [87] and to
impair the upregulation of HIF-1α caused by hypoxia in cell culture [88], while Mg2+ supplementation
helps in reducing axon pathfinding errors caused by hypoxia [89] and has a neuroprotective effect in
preterm birth cases [90]. It is worth noting that HIF-1α activation and pseudo-hypoxic reprogramming
also occurs in cancer, shifting the cell towards a glycolytic phenotype [91].
Int. J. Mol. Sci. 2018, 19, 157 7 of 17
It has been reported that an elevated concentration of TERT within the mitochondrion ([TERT]mito)
may be associated with a prolonged period of reduced psychological stress and improved rest [92]. These
observations are in keeping with the finding that telomere length has been shown to negatively correlate
with increased cortisol responsiveness [93], anxiety and depression [94,95], lower socio-economic
status [96], chronic low-grade inflammation, a higher frequency of adverse early life events [97,98],
and adult daily life stressors [99]. For example, Alzheimer’s dementia (AD) and cardiovascular disease
are characterised by mitochondrial dysfunction and increased ROS production [100,101], while also
being associated with accelerated telomere shortening [102,103].
5. Telomere Length and Disease
Telomere attrition is a hallmark of ageing and age-related disease. However, it has been reported
that individuals with telomeres that are longer than expected, given their age and gender, in healthy
tissue (i.e., “constitutively” long telomeres) may have a higher risk for major cancers than individuals
with “constitutively” shorter telomeres [104]. This is not intuitive, as established physiological
stressors [105–107] have been reported to accelerate age-related telomere shortening. It is therefore of
interest that the majority of cancerous tissues have been reported to display short telomere lengths in
comparison to a previous disease-free measurement [104]. The reasons for this discrepancy remain
unclear. One consideration that may be pertinent to this observation is the fact that telomerase appears
to have a different activity in healthy and cancerous cells [71]. In health, telomerase targets short
telomeres preferentially and extends them with high processivity, while in cancer cells telomerase
appears to target telomeres at random and extend them with low processivity [71]. In combination
with a significantly elevated rate of cell proliferation, this may explain why telomeres tend to be
shorter in cancerous tissue, in spite of the presence of active telomerase. In addition, this leads to the
preservation of average telomere length (TL), providing replicative immortality, while at the same
time allowing the existence of critically short telomeres that act as a source of genomic instability
(t-stumps) [71,108–112].
The impact of TL dynamics remains controversial in oncoscience, with equivocal findings
highlighting an onco-protective role for long telomeres, while other studies indicate a tumour-promoting
association for long telomeres [113,114]. A large number of meta-analyses have also reached conflicting
conclusions, with some reporting short telomeres to be associated with increased cancer risk [115–117],
and others no significant overall effect [118–120]. Interestingly, one meta-analysis found that, while
shorter TL is associated with lower survival, a lower TL ratio of tumour versus healthy tissue was
associated with better survival [121].
It is worth mentioning that these meta-analyses carry significant caveats: results were highly
heterogeneous and often not statistically significant; in addition, correcting for a large number of
potential confounding factors, including age, gender, stress, smoking status, duration of treatment,
etc. was not possible. The difficulty in finding a clear link may reflect the fact that TL can play
a variety of roles in different types and at different stages of cancer. Additionally, epigenetic and
technical issues relating to telomere measurement may also confound many studies. TL, for example,
is a highly heritable genetic trait that displays wide variation across the population. It is significantly
influenced by parental age at the time of birth [122,123]. Issues relating to differing TL measurement
methodology between labs also influence study outcomes and meta analyses and are elegantly covered
by Martin-Ruiz et al. [124]. It is worth noting that most methods provide an average TL value; however,
TL varies significantly between cells and even between chromosomes within the same cell, and a single
uncapped telomere can trigger senescence [125–127]. In addition, many studies use white blood cell
DNA; in such cases, reliability of the results is further limited by the fact that different white blood cell
types have different average TL and their abundance in blood, both in relative and in absolute terms,
can vary significantly depending on the subject and their immunological status [125,128,129]. These
issues may, however, be resolved through the use of intrinsic and extrinsic epigenetic clocks [130–132]
in future studies.
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The role of Mg2+ in cancer prevention and genesis is also complex. Epidemiological studies have
shown an inverse relationship between Mg2+ consumption and cancer prevalence [20,133], and in vitro
studies have indicated that Mg2+ may be protective during the early reprogramming phase [134].
In contrast, Mg2+ supplementation to an established tumour has been shown to promote tumour
growth [134–136]. Interestingly, a similar double-edged relationship, based on tumour progression,
has been established for thiamine supplementation as well [137].
Any pro-growth effect of Mg2+ may be due to a direct DNA stabilization effect, but may also be
attributable to the enhanced performance of the non-oxidative arm of the pentose phosphate pathway
(PPP) through co-operative optimization of transketolase (TK) function by Mg2+ and thiamine [138]
resulting in increased production of ribose-5-phosphate [139].
6. Telomeres, Metabolism, and Circadian Rhythms
The circadian rhythm relies on a transcription-translation feedback loop that regulates numerous
metabolic processes during the day-night cycle and is reported to target 43% of the human protein-coding
genes [140]. In addition, 56 of the top 100 most commonly prescribed medications directly target the
products of circadian genes [140]. In mammals, clock pathways operate in individual cells, but are
synchronised by the master clock in the suprachiasmatic nucleus (SCN) in the hypothalamus, which
in turn is sensitive to light cues from the retina [141,142]. Circadian fluctuations are present in the
sleep/wake cycle, body temperature, hormone production, cell proliferation and DNA repair [143].
TERT mRNA expression has also been reported to oscillate with the circadian rhythm [144].
In mice, deficiency of the clock gene CLOCK has been demonstrated to cause lower telomerase
activity, loss of rhythmicity in TERT mRNA expression, and shorter telomeres [144]. Similarly, hospital
physicians who work a regular day time pattern have regular and rhythmical circadian oscillation of
telomerase activity, while physicians who work a shift pattern in the emergency department lose the
normal circadian rhythms of telomerase activity [144]. This dysregulation of telomerase activity may
contribute to accelerated ageing and be linked to the higher risk seen in shift workers for a variety of
health conditions [145]. In addition, cellular senescence appears to impair circadian rhythms [146],
so it’s tempting to speculate that the accumulation of senescent cells with age may contribute to
the observed disruption of the circadian clock, creating a possible vicious cycle. Loss of circadian
regulation is a feature of mammalian ageing [29].
Given its role in energy metabolism and redox homeostasis, it is perhaps not too surprising that
Mg2+ flux across the cell membrane, especially in the SCN, was recently identified as a regulator of
circadian metabolic oscillations, leading to speculation that [Mg2+] fluctuations may be a component
of the cellular clock [80] and that Mg2+ deficiency may compromise sleep quality and circadian
rhythm [147]. If so, this would indicate that Mg2+ is a key component of cellular ageing and thus
physiological ageing. Furthermore, N-methyl-D-aspartate receptors (NMDARs) within the SCN, which
orchestrate light-induced phase resetting of the circadian rhythm [148], are Mg2+-dependent [149].
An indirect effect of cellular Mg2+ homeostasis that may be mediated through hepatocyte activation of
cortisone remains relatively unexplored from a circadian perspective [150,151]. The increased cortisol
activity may cause further Mg2+ loss and aggravate the circadian disruption [152].
Taken together, these findings indicate that the circadian regulation of telomerase activity and
Mg2+ homeostasis may play an important role in health, disease, and ageing [144,147]. In light of
the twin role of telomerase and Mg2+ in telomere maintenance and oxidative resilience, circadian
disruption could impair the homeostasis and synchronization between telomerase activity and
localisation, local [Mg2+], DNA replication, and redox balance. This could in turn cause accelerated
telomere attrition, increased ROS production, and faster ageing.
7. Conclusions
Telomere structure and function are tightly linked to the homeostatic regulation of cellular
metabolism [153]. Cellular energy production, energy expenditure and protein biosynthesis are
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coupled under the aegis of the MTR (Figure 2) which integrates cellular responses to metabolic and
environmental stressors. As a key ion involved in energy metabolism and DNA/RNA stabilisation,
magnesium has a pervasive role as modulator of many of the pathways that make up the MTR trinity.
This review has indicated the complexities of how such processes might act,either independently,
additively or cumulatively in normative ageing and disease.
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repair the damage it can progress through the cell cycle. Too much damage and the high risk of 
onconeogenesis induces cell death. Senescence, strictly in this simplified scenario, sees the cell carry 
accumulated, sub-lethal damage, as wear and tear, leaving the cell metabolically active, but 
physiologically non-contributory to the function of the tissue and organ in which it resides. The 
pervasive and overlapping roles that TERT (green) and magnesium (orange) play in targeting major 
components of the MRT trinity are highlighted. ER, mTOR/. 
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Figure 2. A schematic of the interplay between mitochondria, telomere nucleo-protein complexes
and proteo-biosynthesis regulation in response to cellular stress/damage. In response to the stress,
the cell will decide how much fuel to burn and energy to expend to repair any damage accrued.
If the cell can repair the damage it can progress through the cell cycle. Too much damage and
the high risk of onconeogenesis induces cell death. Senescence, strictly in this simplified scenario,
sees the cell carry accumulated, sub-lethal damage, as wear and tear, leaving the cell metabolically
active, but physiologically non-contributory to the function of the tissue and organ in which it resides.
The pervasive and overlapping roles that TERT (green) and magnesium (orange) play in targeting
major components of the MRT trinity are highlighted. ER, mTOR/.
One important equitur from the perspective of the MTR is that the use of TL sole y as a cellular
biom rker of ageing to study disease will yield equivocal findings based on dise se con ext. In keepi g
with this, many studies using TL as a singular biomarker of ageing have often yielded equivocal
results. This is particularly pertinent to the use of TL as a biomarker in cancer studies. Given the role
that telomeres play in cellular homeostasis and the multi-faceted nature of the telomere nucleo-protein
complex, a more complete understanding of the various pathways that link cellular metabolism and
telomere homeostasis will help resolve any such equivocation. An examination of the non-canonical
functions of TERT, for example, in the context of the MTR might be of particular interest in this regard.
Another avenue that deserves further study is the impact of disruption of circadian rhythms
on the ability of cells to both co-ordinate maintenance of telomere nucleo-protein complexes and
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regulate ROS production, which may in turn affect cellular and tissue health span and the rate of
physiological ageing.
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